These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 6734405)

  • 21. Oral hypoglycemic agents in type II diabetes mellitus.
    Lubbos H; Miller JL; Rose LI
    Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug interactions of gliclazide and other sulfonylureas in protein binding in vitro and in hypoglycemic effect in rats.
    Fujii T; Nakamura K; Furukawa H; Watanabe M; Kuwashima J; Miyazaki H; Kawashima K; Kuzuya T
    Arzneimittelforschung; 1983; 33(11):1535-7. PubMed ID: 6686448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents.
    de Dios ST; Frontanilla KV; Nigro J; Ballinger ML; Ivey ME; Cawson EA; Little PJ
    J Diabetes Complications; 2007; 21(2):108-17. PubMed ID: 17331859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Physiologic and physiopathologic implications of insulin-receptor interaction (II). Pathologic situations in which changes in insulin-receptor interaction are detected].
    Durán García S; Hernández Herrero C
    Med Clin (Barc); 1984 Apr; 82(14):639-45. PubMed ID: 6376967
    [No Abstract]   [Full Text] [Related]  

  • 25. Blockade of the antinociception induced by diclofenac, but not of indomethacin, by sulfonylureas and biguanides.
    Ortiz MI
    Pharmacol Biochem Behav; 2011 Jul; 99(1):1-6. PubMed ID: 21397627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets.
    Del Guerra S; Marselli L; Lupi R; Boggi U; Mosca F; Benzi L; Del Prato S; Marchetti P
    J Diabetes Complications; 2005; 19(1):60-4. PubMed ID: 15642492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes.
    Jawa AA; Fonseca VA
    Cardiol Clin; 2005 May; 23(2):119-38. PubMed ID: 15694742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of the effects of sulfonylurea exposure on pancreatic beta cell metabolism.
    Brennan L; Hewage C; Malthouse JP; McClenaghan NH; Flatt PR; Newsholme P
    FEBS J; 2006 Nov; 273(22):5160-8. PubMed ID: 17054712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin exocytosis in Goto-Kakizaki rat beta-cells subjected to long-term glinide or sulfonylurea treatment.
    Kawai J; Ohara-Imaizumi M; Nakamichi Y; Okamura T; Akimoto Y; Matsushima S; Aoyagi K; Kawakami H; Watanabe T; Watada H; Kawamori R; Nagamatsu S
    Biochem J; 2008 May; 412(1):93-101. PubMed ID: 18254725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatic effects of oral hypoglycemic drugs.
    Davidoff F
    Fed Proc; 1977 Dec; 36(13):2724-7. PubMed ID: 336410
    [No Abstract]   [Full Text] [Related]  

  • 31. Lack of Ca2+ ionophoretic activity of hypoglycemic sulfonylureas in excitable cells and isolated secretory granules.
    Gylfe E; Hellman B
    Mol Pharmacol; 1982 Nov; 22(3):715-20. PubMed ID: 7155128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mode of action of oral hypoglycaemic agents. II. Sulphonylureas & biguanides in rats.
    Augusti KT; Kurup PA
    Indian J Biochem; 1969 Mar; 6(1):36-9. PubMed ID: 4332123
    [No Abstract]   [Full Text] [Related]  

  • 33. [The pharmacological blockade of protein glycosylation in diabetes mellitus using sulfonylurea derivatives and biguanides].
    Lebedeva EA
    Eksp Klin Farmakol; 1996; 59(5):40-2. PubMed ID: 9026209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral hypoglycemic agents: the pharmacological basis of their clinical use.
    Davidoff F
    R I Med J; 1973 Oct; 56(10):409-14. PubMed ID: 4518221
    [No Abstract]   [Full Text] [Related]  

  • 35. [Biguanides and glucidic homeostasis: effects of metformin and phenformin on the intermediate metabolism and insulin receptors of normal subjects].
    Calafiore R; Pietropaolo M; Basta G; Calcinaro F
    Recenti Prog Med; 1985 Mar; 76(3):152-3. PubMed ID: 3892607
    [No Abstract]   [Full Text] [Related]  

  • 36. [Behavior of lactate and pyruvate in diabetics during ambulatory treatment with biguanides or with a combination of biguanides and sulfonylureas. II].
    Lunetta M; Presti C; Mughini MT; Mughini L
    Clin Ter; 1980 Jun; 93(6):657-72. PubMed ID: 6775864
    [No Abstract]   [Full Text] [Related]  

  • 37. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.
    Fisman EZ; Tenenbaum A; Motro M; Adler Y
    Herz; 2004 May; 29(3):290-8. PubMed ID: 15167955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Shiraki K; Hayakawa M; Shibasaki M
    Metabolism; 2009 Mar; 58(3):379-86. PubMed ID: 19217455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Metabolic effects of butylbiguanide and sulfonylurea (D 860, HB 419, Tolazamide) on isolated human fat cells].
    Ditschuneit H; Faulhaber JD; Ditschuneit HH
    Verh Dtsch Ges Inn Med; 1969; 75():803-5. PubMed ID: 5401641
    [No Abstract]   [Full Text] [Related]  

  • 40. [Free radical scavenging activity of sulfonylureas: a clinical assessment of the effectiveness of gliclazide].
    Jennings PE; Belch JJ
    Ter Arkh; 2001; 73(4):27-31. PubMed ID: 11494442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.